1. Home
  2. MVIS vs NRXS Comparison

MVIS vs NRXS Comparison

Compare MVIS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MicroVision Inc.

MVIS

MicroVision Inc.

N/A

Current Price

$1.85

Market Cap

86.6M

Sector

Technology

ML Signal

N/A

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

N/A

Current Price

$5.97

Market Cap

78.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MVIS
NRXS
Founded
1993
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
86.6M
78.9M
IPO Year
2010
2023

Fundamental Metrics

Financial Performance
Metric
MVIS
NRXS
Price
$1.85
$5.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$2.25
$13.00
AVG Volume (30 Days)
2.4M
89.0K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
23.91
22.13
EPS
N/A
N/A
Revenue
$664,000.00
$3,569,282.00
Revenue This Year
$529.06
$172.91
Revenue Next Year
$168.46
$115.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.89
52 Week Low
$0.23
$2.21
52 Week High
$4.90
$9.33

Technical Indicators

Market Signals
Indicator
MVIS
NRXS
Relative Strength Index (RSI) 49.04 39.42
Support Level $0.56 $5.59
Resistance Level $4.90 $7.54
Average True Range (ATR) 0.34 0.35
MACD -0.18 -0.02
Stochastic Oscillator 5.99 43.67

Price Performance

Historical Comparison
MVIS
NRXS

About MVIS MicroVision Inc.

Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Share on Social Networks: